A Phase 2 interventional study of Erlotinib and Gemcitabine in Non-small Cell Lung Cancer Metastatic, sponsored by Hoffmann-La Roche. Completed at 1 site in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-24.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 5 under way, 2 of them phase 3. erlotinib · Carcinoma, Non-Small-Cell Lung.
Among the 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung, this one is the 167th largest by enrollment of the 200 interventional ones that give a count, is one of 23 that started in 2008, is one of 120 in phase 2, and was the 96th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:
China Medical University Hospital · Sites in Taiwan
Ages 20–70
By country, each count listing its studies:
erlotinib: first FDA approval 2004 (TARCEVA), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
203 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 139 · Phase 3 31 · Phase 4 9
First in 2001; this study’s year is marked. 23 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 58 across the 200 interventional studies. Of the 162 that completed or were terminated, 92 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 203 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche: 5 open now, 16 under way, 8 of them phase 3. Of 161 finished, 96 (60%) have results posted.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 124th largest by enrollment of the 142 interventional ones that give a count, is one of 9 that started in 2008, is one of 56 in phase 2, and was the 24th registered.
Hoffmann-La Roche’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 182 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the efficacy and safety of erlotinib + gemcitabine in chemotherapy-naive participants with unresectable, advanced and/or metastatic non-small cell lung cancer. Participants will receive erlotinib 150 mg orally (po) daily, in combination with gemcitabine 1000 mg/m\^2 intravenously (iv) weekly for 3 weeks of each 4 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received erlotinib 150 mg/day, orally (po) on a continuous schedule in combination with gemcitabine at 1000 mg/m\^2 administered intravenously (iv) on days 1, 8, 15 of each 4 week cycle for 6 cycles as per standard medical care, or until disease progression or participant's withdrawal due to any reason or death.
Drug: Erlotinib · Drug: Gemcitabine
150 mg po daily
Also known as: Tarceva
1000 mg/m\^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
Time to Disease Progression
Time to disease progression or progression free survival (PFS) was defined as the interval between the day of randomization and the date of the first documentation of disease progression or date of death (from any cause), whichever occurs first.
Time frame: From the time of randomization until disease progression or death (up to 193 weeks)]
Overall Response Rate (ORR)
Overall response rate was defined as the percentage of participants who had any evidence of confirmed objective complete response (CR) or partial response (PR), per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) and assessed by computed tomography imaging (CT): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: From the time of randomization until disease progression or death (up to 193 weeks)
Overall Survival
Overall survival was defined as the interval between the day of randomization and the date of death from any cause.
Time frame: From the time of randomization until death (up to 193 weeks)
| Milestone | Erlotinib + Gemcitabine |
|---|---|
| Started | 19 |
| Completed | 4 |
| Not completed | 15 |
| Withdrew: Death | 7 |
| Withdrew: Lost to follow-up | 8 |
Time to disease progression or progression free survival (PFS) was defined as the interval between the day of randomization and the date of the first documentation of disease progression or date of death (from any cause), whichever occurs first.
| weeks | Erlotinib + Gemcitabine |
|---|---|
| Time to Disease Progression | 15 (7 to 36) |
Overall response rate was defined as the percentage of participants who had any evidence of confirmed objective complete response (CR) or partial response (PR), per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) and assessed by computed tomography imaging (CT): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| percentage of participants | Erlotinib + Gemcitabine |
|---|---|
| Overall Response Rate (ORR) | 15.8 |
Overall survival was defined as the interval between the day of randomization and the date of death from any cause.
| weeks | Erlotinib + Gemcitabine |
|---|---|
| Overall Survival | 39 (27 to 51) |
Collected over Up to 28 days after last study drug administration in the study treatment phase (up to 197 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Erlotinib + Gemcitabine | — | 2/19 (10.5%) | 15/19 (78.9%) |
| Event | Erlotinib + Gemcitabine |
|---|---|
| DiarrhoeaGastrointestinal disorders | 1/19 |
| Respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 1/19 |
| Event | Erlotinib + Gemcitabine |
|---|---|
| Anaemia of malignant diseaseBlood and lymphatic system disorders | 7/19 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/19 |
| RashSkin and subcutaneous tissue disorders | 3/19 |
| NeutropeniaBlood and lymphatic system disorders | 2/19 |
| DiarrhoeaGastrointestinal disorders | 2/19 |
| Blood bilirubin increasedInvestigations | 2/19 |
| LeukopeniaBlood and lymphatic system disorders | 1/19 |
| FatigueGeneral disorders | 1/19 |
| Appetite lostMetabolism and nutrition disorders | 1/19 |
| Age, Continuous(years) | Erlotinib + Gemcitabine |
|---|---|
| Mean | 62.47 ± 9.67 |
| Sex: Female, Male(Participants) | Erlotinib + Gemcitabine |
|---|---|
| Female | 3 |
| Male | 16 |
The record gives a start of Aug 2008, a primary completion of Oct 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 5 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Erlotinib · Gemcitabine
Carcinoma, Non-Small-Cell Lung →